Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 30.1%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 549,299 shares, an increase of 30.1% from the November 30th total of 422,094 shares. Based on an average daily volume of 97,160 shares, the days-to-cover ratio is currently 5.7 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 97,160 shares, the days-to-cover ratio is currently 5.7 days.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ EPRX remained flat at $7.73 during trading hours on Tuesday. 16,627 shares of the company traded hands, compared to its average volume of 54,201. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $8.00. The business’s 50 day moving average is $6.18 and its 200 day moving average is $5.67. The stock has a market cap of $277.97 million, a price-to-earnings ratio of -8.89 and a beta of 1.38.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04. On average, analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Quadrature Capital Ltd bought a new stake in shares of Eupraxia Pharmaceuticals during the second quarter worth approximately $61,000. TCI Wealth Advisors Inc. bought a new stake in shares of Eupraxia Pharmaceuticals during the third quarter worth $65,000. Integrated Wealth Concepts LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the third quarter valued at about $71,000. Bank of America Corp DE boosted its position in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Finally, Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $11.67.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.